Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy appoints a chief commercial officer and president for its US division

Moataz Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems, the world's largest manufacturer of radiotherapy equipment for 12 years
US handshake
Before joining Varian Medical, Karmalawy worked at Philips Medical Systems for 10 years where he served in several senior executive roles

Advanced Oncotherapy PLC (LON:AVO) shares jumped higher on Tuesday as the group announced the appointment of Moataz Karmalawy as its chief commercial officer and president of its US division with immediate effect.

The AIM-listed developer of a next-generation proton therapy system for cancer treatment noted that Karmalawy has served as general manager of the Worldwide Particle Therapy Business for Varian Medical Systems Inc., the world's largest manufacturer of radiotherapy equipment for 12 years

READ: Advanced Oncotherapy rises as it obtains international quality standard for LIGHT system

The group pointed out that, whilst at Varian Medical, Karmalawy integrated the acquired proton therapy business into the division, before growing the order book to in excess of US$1bn and achieving a 50% market share of the global particle therapy products market.

Before joining Varian Medical, Karmalawy worked at Philips Medical Systems Inc. for 10 years where he served in several senior executive roles, it added.

Commenting on his appointment, Karmalawy, said: "Advanced Oncotherapy stands out as an incredibly exciting opportunity within the proton therapy market. The global capacity to treat patients with proton therapy has been disappointingly low due to the high cost of traditional proton therapy technologies. 

"As a result, only 1% of patients eligible for radiotherapy are being treated with proton therapy. Advanced Oncotherapy's technology will make this treatment more affordable and accessible to cancer patients worldwide and the LIGHT system has a number of technical advantages to existing technology that will deliver better patient outcomes and offer an accuracy and adjustability beyond legacy technologies."

Advanced Oncotherapy pointed out that his appointment is a non-board appointment.

In afternoon trading, shares in Advanced Oncotherapy were 10% higher at 43.50p.

 -- Adds share price -- 

View full AVO profile View Profile

Advanced Oncotherapy PLC Timeline

Article
September 28 2018

Related Articles

Social media use
Thu
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water
Weight loss
January 07 2019
A deal with Indian firm Zeon Lifesciences in January is the ninth deal the firm has secured for the weight loss product

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use